Market Place
Sourcing Support
Entera Bio Reports Q3 2024 Financial Results & Business Updates
08 Nov 2024 //
GLOBENEWSWIRE
Entera`s EB613 Abstract Selected For ASBMR 2024 Presentation
01 Aug 2024 //
GLOBENEWSWIRE
Entera`s Oral PTH Hypoparathyroidism Candidate EB612 Phase 1 Data
03 Jun 2024 //
GLOBENEWSWIRE
Entera Bio Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide
20 Mar 2024 //
GLOBENEWSWIRE
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
07 Jun 2023 //
GLOBENEWSWIRE
Amgen and Entera Bio call off oral drug delivery partnership after four years
09 May 2023 //
ENDPTS
Entera Bio Provides 2022 Corporate Milestones and Financial Results
31 Mar 2023 //
GLOBENEWSWIRE
Entera Announces Acceptance of Type D Meeting Review to Affirm Design for EB613
15 Feb 2023 //
GLOBENEWSWIRE
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
13 Feb 2023 //
GLOBENEWSWIRE
Entera Bio Provides Corporate Updates and Financial Results for the 3Q 2022
10 Nov 2022 //
GLOBENEWSWIRE
Entera Bio Provides Business Highlights and Financial Results for the 2Q 2022
11 Aug 2022 //
GLOBENEWSWIRE
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
23 Aug 2021 //
GLOBENEWSWIRE
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment
02 Aug 2021 //
GLOBENEWSWIRE
Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment
02 Aug 2021 //
GLOBENEWSWIRE
Entera Bio to Conduct Conference Call to Discuss Phase 2 Results for EB613
28 Jun 2021 //
GLOBENEWSWIRE
Entera Bio Announces Excellent Topline Ph 2 BMD Data for EB613
23 Jun 2021 //
GLOBENEWSWIRE
Entera Bio Receives Foundational Patent for its Oral PTH
17 Jun 2021 //
GLOBENEWSWIRE
Entera Bio Reports Q1 2021 Financial Results and Provides Clinical Updates
20 May 2021 //
GLOBENEWSWIRE
Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study
25 Feb 2021 //
GLOBENEWSWIRE
Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613
07 Jul 2020 //
GLOBENEWSWIRE
Veeva explains rationale for moving deeper into services
03 Dec 2019 //
IN-PHARMATECHNOLOGIST
Entera Bio Establishes U.S. HQ in Wellesley, MA
22 Nov 2019 //
CONTRACT PHARMA
Eli Lilly dishes out first milestone payment for Alzheimer`s deal
24 Sep 2019 //
ENDPTS
Entera Bio Appoints Chief Executive Officer
06 Aug 2019 //
CONTRACT PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.